Chemotherapy for metastatic bladder cancer.

[1]  N. James,et al.  Molecular pathways in bladder cancer: Part 1 , 2005, BJU international.

[2]  N. James,et al.  Molecular pathways in bladder cancer: Part 2 , 2005, BJU international.

[3]  C. Yiannoutsos,et al.  Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Ardavanis,et al.  Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study , 2005, British Journal of Cancer.

[5]  H. Maase.  Pemetrexed in transitional cell carcinoma of the urothelium. , 2004 .

[6]  M. Mencoboni,et al.  Single-Agent Gemcitabine in Previously Untreated Elderly Patients with Advanced Bladder Carcinoma: Response to Treatment and Correlation with the Comprehensive Geriatric , 2004, Oncology.

[7]  W. Oh,et al.  A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. , 2004, Urologic oncology.

[8]  N. James,et al.  A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer , 2004, British Journal of Cancer.

[9]  G. Hall,et al.  Systemic chemotherapy for patients with bladder cancer--current controversies and future directions. , 2004, Cancer treatment reviews.

[10]  J. Manola,et al.  Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium , 2004, Cancer.

[11]  M. Aristides,et al.  Cost–utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer , 2004, Expert review of pharmacoeconomics & outcomes research.

[12]  A. Yagoda.  Phase-II trials in patients with urothelial tract tumors , 1983, Cancer Chemotherapy and Pharmacology.

[13]  M. Edelman,et al.  Platinum‐free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma , 2004, Cancer.

[14]  S. Baltacı,et al.  Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy. , 2003, European urology.

[15]  R. Figlin,et al.  A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma , 2003, Cancer.

[16]  P. Cooke,et al.  BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. , 2003, Oncology reports.

[17]  S. Culine,et al.  Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study. , 2003, Anticancer research.

[18]  J. Baselga,et al.  Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine , 2002, Cancer.

[19]  L. Seymour,et al.  Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. , 2002, Urologic oncology.

[20]  D. Neal,et al.  Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[21]  L. Collette,et al.  Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Bajorin,et al.  Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. , 2001, The Journal of urology.

[23]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Baselga,et al.  Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. Oh,et al.  Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  P. Cooke,et al.  Bcl‐2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy , 2000, BJU international.

[27]  L. Crinò,et al.  Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  D. Neal,et al.  TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  I. Tannock,et al.  Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Bateman,et al.  Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  J. Bacik,et al.  Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Parmar,et al.  A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. , 1998, British Journal of Cancer.

[33]  H. Akaza,et al.  Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group. , 1998, Japanese journal of clinical oncology.

[34]  G. Luporini,et al.  A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum , 1998 .

[35]  I. Tannock,et al.  Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Ribas,et al.  Carboplatin‐based versus cisplatin‐based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma , 1997, Cancer.

[37]  T. Kuzel,et al.  Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  I. Tannock,et al.  Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Mazumdar,et al.  Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Mazumdar,et al.  Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  P. Johnson,et al.  Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. , 1997, British Journal of Cancer.

[42]  W. See,et al.  Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. , 1996, The Journal of urology.

[43]  S. Fosså,et al.  Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. , 1996, British Journal of Cancer.

[44]  F. Selvaggi,et al.  Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin). , 1996, Journal of chemotherapy.

[45]  S. Mondillo,et al.  Comparison between a cisplatin‐containing regimen and a carboplatin‐containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study , 1996, Cancer.

[46]  G. Peters,et al.  Interaction between cisplatin and gemcitabine in vitro and in vivo. , 1995, Seminars in oncology.

[47]  D. Neuberg,et al.  Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J. Louis,et al.  Carboplatin and urothelial tumors. , 1993, Oncology.

[49]  C. Barton,et al.  Carboplatin-based chemotherapy for bladder cancer. , 1993, Cancer treatment reviews.

[50]  I. Tannock,et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  J. Droz,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. , 1991, European journal of cancer.

[52]  J. Prüger,et al.  Carboplatin, Methotrexate and Vinblastin (Carbo‐MV) for Advanced Urothelial Cancer A Phase II Trial , 1991, American journal of clinical oncology.

[53]  D. Trump,et al.  RANDOMIZED PHASE II EVALUATION OF CARBOPLATIN AND CHIP IN ADVANCED TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM , 1990 .

[54]  M. Igawa,et al.  Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. , 1990, The Journal of urology.

[55]  C. Logothetis,et al.  A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  J. Waxman.  Chemotherapy for metastatic bladder cancer. Is there new hope? , 1990, British journal of urology.

[57]  N. Geller,et al.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.

[58]  S. Fosså,et al.  Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder. , 1989, British journal of urology.

[59]  I. Tannock,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. , 1989, The Journal of urology.

[60]  R. Kefford,et al.  A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  K. Sikora,et al.  New combination chemotherapy programme for bladder cancer. , 1989, British journal of urology.

[62]  N. Geller,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. , 1988, The Journal of urology.

[63]  V. Reuter,et al.  Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. , 1988, The Journal of urology.

[64]  M. Troner,et al.  Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial. , 1987, The Journal of urology.

[65]  S. Fosså,et al.  Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. , 1987, The Journal of urology.

[66]  R. Oliver,et al.  Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer. , 1986, British journal of urology.

[67]  F. Freiha,et al.  The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study. , 1985, The Journal of urology.

[68]  F. Freiha,et al.  Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  J. Carmichael,et al.  Cis-platin and methotrexate in the treatment of transitional cell carcinoma of the urinary tract. , 1985, British journal of urology.

[70]  R. Oliver.  Chemotherapy of invasive carcinoma of the bladder. , 1985, The Australian and New Zealand journal of surgery.

[71]  P. Elson,et al.  Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  N. Geller,et al.  Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. , 1985, The Journal of urology.

[73]  R. Wines,et al.  Initial intravenous cis-platinum therapy: improved management for invasive high risk bladder cancer? , 1985, The Journal of urology.

[74]  E. Crawford,et al.  Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study. , 1985, Cancer treatment reports.

[75]  P Dawson-Edwards,et al.  Cis-diamminedichloroplatinum (DDP) as initial treatment of invasive bladder cancer. , 1984, British journal of urology.

[76]  E. Maiello,et al.  Cis-Diamminedichloroplatinum Activity in Bidimensionally Measurable Metastatic Lesions of Bladder Carcinoma , 1984, Tumori.

[77]  M. Soloway,et al.  A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group a study , 1983, Cancer.

[78]  C. Coltman,et al.  Adriamycin versus adriamycin plus cis‐diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma: A Southwest Oncology Group study , 1983, American journal of clinical oncology.

[79]  R. Natale,et al.  Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors , 1982, Cancer.

[80]  H. Bloom,et al.  A Phase 2 Study of Cis‐platinum in Patients with Recurrent Bladder Carcinoma , 1981 .

[81]  W. Whitmore,et al.  Methotrexate: An active drug in bladder cancer , 1981, Cancer.

[82]  M. Soloway,et al.  Cis‐diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer , 1981, Cancer.

[83]  A. Bartolucci,et al.  A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. , 1981, The Journal of urology.

[84]  H. Herr.  Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer. , 1980, The Journal of urology.

[85]  P. Peters,et al.  Cis-Diamminebichloroplatinum as a Therapeutic Agent in Metastatic Transitional Cell Carcinoma , 1980 .

[86]  C. Merrin.  Treatment of advanced bladder cancer with cis-diamminedichloroplatinum (II NSC 119875): a pilot study. , 1978, The Journal of urology.

[87]  H. Bloom,et al.  The treatment of advanced bladder cancer with methotrexate. , 1977, British journal of urology.

[88]  B. Hoogstraten,et al.  Dose response evaluation of adriamycin in human neoplasia , 1977, Cancer.

[89]  W. Whitmore,et al.  Adriamycin in advanced urinary tract cancer. Experience in 42 patients and review of the literature , 1977, Cancer.

[90]  I. Maclennan,et al.  Effects of varying the interval between courses of methotrexate on its myelotoxic and anti-leukaemic activities. , 1977, British Journal of Cancer.

[91]  M. Pavone‐Macaluso.  Single-drug chemotherapy of bladder cancer with adriamycin, VM-26 or bleomycin. A phase II multicentric, co-operative study. , 1976, European urology.

[92]  J. E. Freeman,et al.  Methotrexate treatment for advanced bladder cancer. , 1974, British journal of urology.